Company Profiles

driven by the PitchBook Platform

Adrenomed

Adrenomed
2009 FOUNDED
PRIVATE STATUS
Later Stage VC LATEST DEAL TYPE
1 INVESTORS
Description

Developer of biopharmaceutical products. The company is focused on development of the drug Adrecizumab, as a treatment for sepsis.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Primary Office
Neuendorfstra├če 15A
16761 Hennigsdorf
Germany
+49 (0)33 0220 7780
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Adrenomed’s full profile, request a free trial.

Adrenomed Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Later Stage VC 01-Jan-2014 Completed Generating Revenue
To view this company’s complete deal history including valuation and funding request access »

Adrenomed Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
BC Brandenburg Capital Venture Capital Minority 000 0000 000000 0

Adrenomed Executive Team (5)

Name Title Board
Seat
Contact
Info
Bernd Wegener Chief Executive Officer & Board Member & Co-Founder
Mathias Schroedter Ph.D Chief Operating Officer
Andreas Bergmann Chief Scientific Officer & Board Member & Co-Founder
Frauke Hein Ph.D Chief Business Officer
Paul Scigalla Chief Medical Officer

Adrenomed Board Members (4)

Name Representing Role Since Contact
Info
Andreas Bergmann Adrenomed Chief Scientific Officer & Board Member & Co-Founder 000 0000
Bernd Wegener Adrenomed Chief Executive Officer & Board Member & Co-Founder 000 0000
Gerald Moeller Adrenomed Co-Founder & Supervisory Board Member 000 0000
Renke L├╝hrs Adrenomed Chairman 000 0000